Discount Price May Position Aubagio For Greater Than Expected Uptake In Multiple Sclerosis
Wall Street projects modest sales for Sanofi/Genzyme’s recently approved MS drug, but by pricing it well below Gilenya and somewhat below established, widely used injectable drugs, the companies may position Aubagio for first-line use and greater than anticipated adoption by payers.
You may also be interested in...
Britain’s NICE wants more data to address uncertainties about the clinical and cost-effectiveness of Genzyme’s oral MS drug Aubagio.
The company expects dimethyl fumarate’s strong efficacy and favorable safety and tolerability profile to be an advantage against other oral multiple sclerosis drugs.
The biopharma released the new name and cited a rough pricing range for multiple sclerosis drug BG-12, which has a late March PDUFA date. But management tapped the brakes a bit on analyst sales estimates, offering a few words of caution.